Novo Nordisk strikes second licensing deal since frosty capital-markets day
MarketWatch· Steve Goldstein· Sep 29, 2026 · 9:45 AM
Novo Nordisk on Tuesday struck its second licensing deal since receiving a poor reception from investors after presenting its long-term strategy.
This is a summary. Read the complete story at MarketWatch below.
Read full article at MarketWatchRelated Stories
marketsabout 3 hours ago
Morgan Stanley’s Mike Wilson says an S&P 500 correction may be exactly what the market needs
The chief U.S. equity strategist at the investment bank favors large-capitalization quality companies.
MarketWatch
marketsabout 3 hours ago
Two stock picks from a money manager who expects small-caps to roar in 2027
Calamos Investments manager Brandon Nelson’s four-star fund is betting on financial services apps.
MarketWatch
marketsabout 5 hours ago
Here’s where TSMC is reportedly eyeing a second U.S. site for a chip-making hub
Taiwan Semiconductor Manufacturing Co., the Taiwanese contract chipmaker that makes semiconductors for Nvidia among others, is reportedly eyeing a second site in the U.S.
MarketWatch